JP2018021046A5 - - Google Patents

Download PDF

Info

Publication number
JP2018021046A5
JP2018021046A5 JP2017155657A JP2017155657A JP2018021046A5 JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5 JP 2017155657 A JP2017155657 A JP 2017155657A JP 2017155657 A JP2017155657 A JP 2017155657A JP 2018021046 A5 JP2018021046 A5 JP 2018021046A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical composition
dosage form
unit dosage
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017155657A
Other languages
English (en)
Other versions
JP6448726B2 (ja
JP2018021046A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018021046A publication Critical patent/JP2018021046A/ja
Publication of JP2018021046A5 publication Critical patent/JP2018021046A5/ja
Application granted granted Critical
Publication of JP6448726B2 publication Critical patent/JP6448726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)




  1. の化合物、またはその医薬的に許容可能な塩、溶媒和物しくは立体異性体
    [式中、
    Yは、C=Oあり、
    は、ナフチルアルキルであり、Rは、アルコキシ、ハロ、アルキおよびアルキルスルホニルから選択される1つまたは複数の基で置換されていてもよい]。
  2. が、アルコキシ、ハロ、アルキルおよびアルキルスルホニルから選択される1つまたは複数の置換基で置換されている、請求項に記載の化合物。
  3. ナフチルメチルある、請求項1または2に記載の化合物。
  4. 1−ナフト−2−イルエチルである、請求項1に記載の化合物。
  5. 請求項1からのいずれか1項に記載の化合物、またはその医薬的に許容可能な塩、溶媒和物もしくは立体異性体を含有する医薬組成物。
  6. 癌、血管新生関連障害、疼痛、黄斑変性もしくはその関連症候群、皮膚病、肺障害、アスベスト関連障害、寄生虫病、免疫不全障害、CNS障害、CNS損傷、アテローム性動脈硬化症もしくはその関連障害、機能不全睡眠もしくはその関連障害、感染症、異常ヘモグロビン症もしくはその関連障害、またはTNFα関連障害の治療、維持または予防のための請求項5記載の医薬組成物。
  7. 1または複数種類の追加の活性成分と併用されることを特徴とする、請求項6に記載の医薬組成物。
  8. 前記疾患が、癌であり、前記追加の活性薬剤が、癌ワクチンである、請求項7に記載の医薬組成物。
  9. 請求項1ないし4に記載の化合物を含む単位投与剤形。
  10. 経口または非経口投与される請求項9記載の単位投与剤形。
  11. 経口投与に適する、請求項10に記載の単位投与剤形。
  12. 錠剤またはカプセルである、請求項10に記載の単位投与剤形。
JP2017155657A 2007-03-20 2017-08-10 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 Active JP6448726B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91932307P 2007-03-20 2007-03-20
US60/919,323 2007-03-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015211991A Division JP6373818B2 (ja) 2007-03-20 2015-10-28 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018021046A JP2018021046A (ja) 2018-02-08
JP2018021046A5 true JP2018021046A5 (ja) 2018-06-14
JP6448726B2 JP6448726B2 (ja) 2019-01-09

Family

ID=39719168

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009554563A Withdrawn JP2010522170A (ja) 2007-03-20 2008-03-19 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2014129790A Active JP5927241B2 (ja) 2007-03-20 2014-06-25 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2015211991A Active JP6373818B2 (ja) 2007-03-20 2015-10-28 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2017155657A Active JP6448726B2 (ja) 2007-03-20 2017-08-10 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009554563A Withdrawn JP2010522170A (ja) 2007-03-20 2008-03-19 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2014129790A Active JP5927241B2 (ja) 2007-03-20 2014-06-25 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2015211991A Active JP6373818B2 (ja) 2007-03-20 2015-10-28 4’−o−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Country Status (25)

Country Link
US (6) US8153659B2 (ja)
EP (2) EP2142534B1 (ja)
JP (4) JP2010522170A (ja)
KR (3) KR20090121400A (ja)
CN (2) CN103641814A (ja)
AR (1) AR065810A1 (ja)
AU (1) AU2008229383B2 (ja)
BR (1) BRPI0809011A8 (ja)
CA (1) CA2681633C (ja)
CL (1) CL2008000805A1 (ja)
CO (1) CO6231033A2 (ja)
CR (2) CR11036A (ja)
EC (1) ECSP099663A (ja)
ES (2) ES2601131T3 (ja)
IL (1) IL200990A (ja)
MX (1) MX2009010082A (ja)
MY (1) MY180812A (ja)
NI (1) NI200900170A (ja)
NZ (2) NZ599199A (ja)
PE (1) PE20081894A1 (ja)
RU (1) RU2471794C2 (ja)
UA (1) UA97976C2 (ja)
UY (1) UY30977A1 (ja)
WO (1) WO2008115516A2 (ja)
ZA (1) ZA200906497B (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
ZA200704964B (en) * 2004-12-01 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
KR20090121400A (ko) 2007-03-20 2009-11-25 셀진 코포레이션 4'-o-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
WO2009085234A2 (en) * 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
CA2781888C (en) * 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
SI3202461T1 (sl) * 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
AU2013245487B2 (en) * 2010-02-11 2016-03-10 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2016203826B2 (en) * 2010-02-11 2018-05-17 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012174488A2 (en) * 2011-06-15 2012-12-20 Nono, Inc. Agents and methods for treating ischemic and other diseases
CN102731853B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油橡胶
CN102731851B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 一种耐油橡胶
CN102731850B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油耐磨橡胶
US9133161B2 (en) * 2012-07-27 2015-09-15 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
CA2879151C (en) 2012-08-09 2021-03-30 Celgene Corporation Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
SG11201500983RA (en) 2012-08-09 2015-04-29 Celgene Corp Treatment of immune-related and inflammatory diseases
JP6347782B2 (ja) * 2012-08-09 2018-06-27 セルジーン コーポレイション 3−(4−((4−(モルホリノメチル)ベンジル)オキシ)−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンを使用する癌の治療方法
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140314752A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
WO2015179276A1 (en) 2014-05-19 2015-11-26 Celgene Corporation 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
KR102191256B1 (ko) * 2014-10-30 2020-12-15 강푸 바이오파마슈티칼즈 리미티드 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10159665B2 (en) 2016-03-23 2018-12-25 Louis Habash Preventing amyloid plaque formation by treating a human subject with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
CA3056059C (en) * 2016-03-23 2023-02-14 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
KR20220028178A (ko) 2016-12-16 2022-03-08 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
SG11202000143PA (en) 2017-07-10 2020-02-27 Celgene Corp Antiproliferative compounds and methods of use thereof
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
CN111278815B (zh) 2017-09-04 2024-03-08 C4医药公司 戊二酰亚胺
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
WO2019209692A1 (en) 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
JOP20210001A1 (ar) * 2018-07-10 2021-01-05 Novartis Ag مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
JP7168773B2 (ja) * 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
WO2020092950A1 (en) * 2018-11-01 2020-05-07 Northwestern University Targeting pleckstrin-2 for treating cancer
CN111285850B (zh) 2018-12-06 2022-04-22 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
FI3962489T3 (fi) * 2019-02-22 2023-06-09 Elkem Silicones Usa Corp Lääkeaineen antamiseen tarkoitettu silikonikoostumus vaikuttavan aineen eluution parantamiseksi
CN111747924B (zh) * 2019-03-29 2023-11-10 华东师范大学 一类来那度胺/泊马度胺类似物及其应用
BR112021019669A2 (pt) 2019-04-12 2021-12-07 C4 Therapeutics Inc Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
TWI762939B (zh) 2019-05-31 2022-05-01 大陸商海思科醫藥集團股份有限公司 Btk抑制劑環衍生物及其製備方法和藥學上的應用
KR20220145366A (ko) * 2020-02-25 2022-10-28 상하이테크 유니버시티 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용
AU2021255966A1 (en) * 2020-04-17 2022-11-17 Escient Pharmaceuticals, Inc. Modulators of mas-related G-protein receptor X4 and related products and methods
MX2023000868A (es) * 2020-07-20 2023-02-22 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
TW202241872A (zh) * 2021-01-05 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
KR20240136385A (ko) 2022-01-19 2024-09-13 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 황을 함유하는 이소인돌린계 유도체의 결정형
WO2024097932A1 (en) * 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Compounds and their use for treatment of hemoglobinopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
KR19980074060A (ko) * 1997-03-21 1998-11-05 김윤배 신규한 치환된 3,4-디알콕시페닐 유도체
TR200101500T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN1867331B (zh) * 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
ZA200704964B (en) 2004-12-01 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
MX2007007424A (es) * 2004-12-24 2007-07-17 Astrazeneca Ab Derivados de amina.
KR20090121400A (ko) * 2007-03-20 2009-11-25 셀진 코포레이션 4'-o-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2018021046A5 (ja)
JP2018048154A5 (ja)
RU2018133298A (ru) Способы применения агонистов fxr
JP2013519675A5 (ja)
JP2008528514A5 (ja)
JP2017528507A5 (ja)
JP2017528503A5 (ja)
JP2016528301A5 (ja)
JP2010504973A5 (ja)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2009506117A5 (ja)
JP2018537507A5 (ja)
JP2017531619A5 (ja)
JP2014198723A5 (ja)
JP2020097577A5 (ja)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2017522300A5 (ja)
JP2016510326A5 (ja)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2020529995A5 (ja)
JP2019218379A5 (ja)
JP2014148552A5 (ja)
PH12017501829A1 (en) Pharmaceutical formulations
JP2019507786A5 (ja)
JP2020515523A5 (ja)